Development of a predictive scoring model for non-response to intravenous immunoglobulin in Kawasaki disease
HUANG Yi-Xu, HUANG Yu, PI Guang-Huan
Department of Pediatrics, Sichuan Provincial Women's and Children's Hospital/Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu 610045, China
Abstract:Objective To explore the predictive factors for non-response to intravenous immunoglobulin (IVIG) in children with Kawasaki disease (KD) and to establish an IVIG non-response prediction scoring model for the Sichuan region. Methods A retrospective study was conducted by collecting clinical data from children with KD admitted to four tertiary hospitals in Sichuan Province between 2019 and 2023. Among them, 940 children responded to IVIG, while 74 children did not respond. Multivariate logistic regression analysis was used to identify the predictive factors for non-response to IVIG and to establish a predictive scoring model. The model's effectiveness was assessed using the receiver operating characteristic curve (ROC) and validated with an independent dataset. Results Multivariate logistic regression analysis showed that the platelet-to-lymphocyte ratio (PLR), hemoglobin (Hb), serum creatinine, aspartate aminotransferase (AST), and platelet count (PLT) were closely related to non-response to IVIG in children with KD (P<0.05). Based on these indicators, a predictive scoring model was established: PLR > 199, 0.4 points; Hb ≤ 116 g/L, 4 points; AST > 58 U/L, 0.2 points; serum creatinine > 38 μmol/L, 3.9 points; PLT count ≤ 275 × 109/L, 0.3 points. Using this model, children with KD were scored, and a total score greater than 4.3 was considered high risk of non-response to IVIG. The sensitivity of the model in predicting non-response to IVIG was 77.0%, specificity was 65.7%, and the area under the ROC curve was 0.746 (95%CI: 0.688-0.805). Conclusions The predictive scoring model based on PLR, Hb, serum creatinine, AST, and PLT demonstrates good predictive performance for non-response to IVIG in children with KD in the Sichuan region and can serve as a reference for clinical decision-making.
HUANG Yi-Xu,HUANG Yu,PI Guang-Huan. Development of a predictive scoring model for non-response to intravenous immunoglobulin in Kawasaki disease[J]. CJCP, 2025, 27(1): 75-81.
de Graeff N, Groot N, Ozen S, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease: the SHARE initiative[J]. Rheumatology (Oxford), 2019, 58(4): 672-682. PMID: 30535127. DOI: 10.1093/rheumatology/key344.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model[J]. BMJ, 2020, 368: m441. PMID: 32188600. DOI: 10.1136/bmj.m441.
Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease[J]. J Pediatr, 2006, 149(2): 237-240. PMID: 16887442. DOI: 10.1016/j.jpeds.2006.03.050.
Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease[J]. Circulation, 2006, 113(22): 2606-2612. PMID: 16735679. DOI: 10.1161/CIRCULATIONAHA.105.592865.
Fu PP, Du ZD, Pan YS. Novel predictors of intravenous immunoglobulin resistance in Chinese children with Kawasaki disease[J]. Pediatr Infect Dis J, 2013, 32(8): e319-e323. PMID: 23446442. DOI: 10.1097/INF.0b013e31828e887f.
Lin MT, Chang CH, Sun LC, et al. Risk factors and derived Formosa score for intravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease[J]. J Formos Med Assoc, 2016, 115(5): 350-355. PMID: 25910931. DOI: 10.1016/j.jfma.2015.03.012.
Yang S, Song R, Zhang J, et al. Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing[J]. Arch Dis Child, 2019, 104(3): 262-267. PMID: 30026252. DOI: 10.1136/archdischild-2017-314512.
Wu S, Liao Y, Sun Y, et al. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in children[J]. World J Pediatr, 2020, 16(6): 607-613. PMID: 32232677. DOI: 10.1007/s12519-020-00348-2.
Xu B, Zhang Q, Du J, et al. Prediction of intravenous immunoglobulin-resistant Kawasaki disease: a research hotspot[J]. Sci Bull (Beijing), 2023, 68(2): 121-124. PMID: 36681588. DOI: 10.1016/j.scib.2023.01.019.
Kanai T, Takeshita S, Kawamura Y, et al. The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study[J]. Heart Vessels, 2020, 35(10): 1463-1472. PMID: 32449049. DOI: 10.1007/s00380-020-01622-z.
Grignani R, Rajgor DD, Leow YG, et al. A novel model for predicting non-responsiveness to intravenous immunoglobulins in Kawasaki disease: the Singapore experience[J]. J Paediatr Child Health, 2019, 55(8): 962-967. PMID: 30520192. DOI: 10.1111/jpc.14329.
Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment[J]. Eur J Pediatr, 2007, 166(2): 131-137. PMID: 16896641. DOI: 10.1007/s00431-006-0223-z.
Moon KP, Kim BJ, Lee KJ, et al. Prediction of nonresponsiveness to medium-dose intravenous immunoglobulin (1 g/kg) treatment: an effective and safe schedule of acute treatment for Kawasaki disease[J]. Korean J Pediatr, 2016, 59(4): 178-182. PMID: 27186228. PMCID: PMC4865641. DOI: 10.3345/kjp.2016.59.4.178.